Evidence map›Paper›PMID 38509672›Full record

ArticleCurrent neuropharmacology2024

Metabotropic Glutamate Receptors Type 3 and 5 Feature the "NeuroTransmitter-type" of Glioblastoma: A Bioinformatic Approach.

Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia, Antonietta Arcella

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current neuropharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matteo CaridiDivision of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy.
Marika AlborghettiDepartment of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Valeria PellicelliInternal Medicine, Sapienza University of Rome, Rome, Italy.
Rosamaria OrlandoDepartment of Physiology and Pharmacology, University Sapienza of Roma, Rome, Italy.
Francesco Ernesto PontieriDepartment of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Giuseppe BattagliaDepartment of Physiology and Pharmacology, University Sapienza of Roma, Rome, Italy.
Antonietta ArcellaIRCCS Neuromed, Pozzilli, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal.

objectiveContribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine.

methodsHere, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas.

resultsThe analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature.

conclusionOur findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM.

Indexed as

Brain NeoplasmsComputational BiologyGlioblastomaReceptors, Metabotropic GlutamateHumansNeurotransmitter AgentsReceptor, Metabotropic Glutamate 5metabotropic glutamate receptor 3Neurotransmitter AgentsReceptor, Metabotropic Glutamate 5Receptors, Metabotropic Glutamateglioblastoma multiformeGliomaglutamateimmunological signaturemetabolic signature.metabotropic glutamate receptors type 3 and type 5neurotransmitter- GBM

Identifiers

PMID38509672
PMCPMC11284726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.